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Figure S1 The expression of eight candidate genes identified in the array was validated by RT-PCR in breast MCF7 and colon HT-29 cancer cells. Numbers indicate fold changes in the expression levels of the genes upon incubation of the cells with SB203580 to inhibit p38 MAPK signaling. Genes downregulated at least 1.5 fold in both cell lines are shadowed Table S2 . Sequences of primers used for RT-PCR analysis A. MCF7 cells were transfected with siRNAs (50 nM) either control or against p38α, p38β or both together. After 48 h, cells were treated for 8 h with cisplatin (CDDP, 100 μM). Total lysates were analyzed by immunoblotting with the indicated antibodies. The upper blot was incubated first with the p38β antibody and then with the p38α antibody. B. HT-29 cells were transfected with siRNAs (50 nM) either control or against JNK1/2. After 48 h, cells were incubated for 2 h in the presence or absence of PH-797804 (PH) and then treated for 24 h with cisplatin (CDDP, 100 μM). Cell death was quantified by staining with propidium iodide (PI) and Annexin V. Total cell lysates were analyzed by immunoblotting with the indicated antibodies (right panel). C. HT-29 cells were infected with lentiviruses expressing shRNAs against JNK1 or JNK2 or a non-targeting control. Pools of cells were incubated overnight in the presence or absence of SB203580 (SB, 10 μM) and then treated for 8 h with cisplatin (CDDP, 100 μM). Total cell lysates were analyzed by immunoblotting with the indicated antibodies. A. Cells were treated for 1 h with a mixture of NAC and GSH antioxidants (AOX) or incubated overnight with SB203580 (SB, 10 μM) and then plated for clonogenic assays. Colonies were dissolved in methanol and the absorbance reads (540 nm) are represented in the bar diagrams. B. Cells were incubated for 48 h either with two different siRNAs against p38α (#1 and #2) or with a scrambled siRNA (siCtrl) as a control. Total cell lysates were analyzed by immunoblotting with the indicated antibodies (upper blot). For clonogenic assays, siRNA-treated cells were treated for 1 h with AOX as in (A) followed by 1 h incubation with cisplatin (CDDP) and then plated. Colonies were dissolved in methanol and the absorbance reads (540 nm) are represented in the bar diagrams. A. MCF7 cells were incubated with the indicated concentrations of ASK1 inhibitor (ASK1 inh) overnight and then irradiated with UV (50 J/m 2 ) followed by 30 min incubation at 37ºC. Total cell lysates were analyzed by immunoblotting with the indicated antibodies. B. MCF7 cells were incubated overnight with SB203580 (p38 inh, 10 μM) and/or ASK1 inhibitor (10 μM) followed by cisplatin (CDDP, 100 μM) for 8 h. Total cell lysates were analyzed by immunoblotting with the indicated antibodies. Then, a second injection of CDDP was administered to the mice and tumor growth was monitored for up to 70 days . Tumor size was measured at the indicated times and normalized relative to the original size of each tumor when the treatment began. The graph compiles the results of three independent experiments, in which at least four mice per condition were used. Figure S12 . MCF7, SW620 and HT-29 cells were treated with increasing concentrations of cisplatin (CDDP) with or without SB203580 (SB, 10 μM) for 24 h. Cell viability was measured using the MTT assay. The percentages of viable cells relative to non-treated cells were calculated.
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